Join Growin Stock Community!

Edgewise therapeutics, inc.EWTX.US Overview

US StockHealthcare
(No presentation for EWTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EWTX AI Insights

EWTX Overall Performance

EWTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EWTX Recent Performance

-3.42%

Edgewise therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

EWTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EWTX Key Information

EWTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EWTX Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Price of EWTX

EWTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EWTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.58
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.77
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.58
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.77
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is EWTX's latest earnings report released?

    The most recent financial report for Edgewise therapeutics, inc. (EWTX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EWTX's short-term business performance and financial health. For the latest updates on EWTX's earnings releases, visit this page regularly.

  • How much debt does EWTX have?

    As of the end of the reporting period, Edgewise therapeutics, inc. (EWTX) had total debt of 3.99M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does EWTX have?

    At the end of the period, Edgewise therapeutics, inc. (EWTX) held Total Cash and Cash Equivalents of 61.15M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is EWTX's EPS continuing to grow?

    According to the past four quarterly reports, Edgewise therapeutics, inc. (EWTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.48. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of EWTX?

    Edgewise therapeutics, inc. (EWTX)'s Free Cash Flow (FCF) for the period is -38.67M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 41.99% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of EWTX?

    The latest valuation data shows Edgewise therapeutics, inc. (EWTX) has a Price-To-Earnings (PE) ratio of -18.96 and a Price/Earnings-To-Growth (PEG) ratio of -0.62. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.